Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27046896 | 1.00 | EPHX1 (0.52) | EPHX1EPHX2GPR84SMN1; SMN2ALDH1A1 | |
| SCHEMBL28519865 | 0.87 | SMN1; SMN2 (0.60) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL7888130 | 0.87 | SMN1; SMN2 (0.60) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL28518219 | 0.85 | SMN1; SMN2 (0.62) | EPHX1EPHX2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL21443034 | 0.82 | EPHX1 (0.50) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL27587755 | 0.81 | GPR84 (0.66) | EPHX1EPHX2GPR84ALDH1A1KMT2A | |
| SCHEMBL21442874 | 0.78 | SMN1; SMN2 (0.75) | EPHX1EPHX2SMN1; SMN2ALDH1A1 | |
| Hexadecanoic Acid Cyclohexylamide SCHEMBL1456860 | 0.78 | SMN1; SMN2 (0.75) | EPHX1EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL21443012 | 0.78 | SMN1; SMN2 (0.75) | EPHX1EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5002618 | 0.78 | SMN1; SMN2 (0.75) | EPHX1EPHX2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-08-12 | — | — | US | disclosed |
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | Technische Universität München (DE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210247400-A1 | ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF | PGLS, LIPE, LYPLA2 | EPHX1 1826/4885EPHX2 1735/4885GPR84 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.